@benny171a @lotzof_gas @activia513 @krtmd @jonathanchait Clinical trial of BA.1 bivalent vaccine.
"Phase 2/3 trial found that a booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies’ current COVID-19 vaccine" https://www.pfizer.com/news/pr...
@benny171a @lotzof_gas @activia513 @krtmd @jonathanchait BA.1 二价疫苗的临床试验。
“第 2/3 期试验发现，与公司目前的 COVID-19 疫苗相比，两种 Omicron 适应疫苗候选者的加强剂量引发了对 Omicron BA.1 的显着更高的免疫反应”https://www.pfizer.com/新闻/公关...